Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

22.24USD
21 Jul 2017
Change (% chg)

$0.07 (+0.32%)
Prev Close
$22.17
Open
$22.19
Day's High
$22.82
Day's Low
$21.98
Volume
731,376
Avg. Vol
597,882
52-wk High
$24.88
52-wk Low
$11.42

NKTR.OQ

Chart for NKTR.OQ

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $3,450.53
Shares Outstanding(Mil.): 155.15
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 213.75 15.85
EPS (TTM): -1.37 -- --
ROI: -45.19 -7.93 -8.31
ROE: -889.92 -9.29 -7.95

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Jul 21 2017

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

July 21 European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

Jul 21 2017

BRIEF-Nektar presents findings from two phase 1 clinical studies of NKTR-214

* Presented new findings from two phase 1 clinical studies of NKTR-214, nektar's lead immuno-oncology candidate

Jun 05 2017

BRIEF-Nektar Therapeutics reports Q1 revenue $24.7 million

* Nektar Therapeutics reports financial results for the first quarter of 2017

May 09 2017

Nektar's opioid painkiller succeeds in key late-stage study

Nektar Therapeutics said its experimental opioid, designed to achieve pain relief without the euphoria that can lead to abuse and addiction, succeeded in a key late-stage study.

Mar 20 2017

UPDATE 2-Nektar's opioid painkiller succeeds in key late-stage study

* Co to discuss next steps with FDA, looks for strategic partner

Mar 20 2017

Nektar's opioid painkiller succeeds in key late-stage study

March 20 Nektar Therapeutics said its experimental opioid, designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study.

Mar 20 2017

BRIEF-Nektar Therapeutics Q4 loss per share $0.28

* Nektar Therapeutics reports fourth quarter and year-end 2016 financial results

Mar 01 2017

Earnings vs. Estimates